Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted ...
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free ...
Investigators stated that the results support the proposed mechanism that both retained HER2 expression and elevated CD47 levels may drive efficacy through enhanced antibody-dependent cellular ...
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to ...
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to ...
In an interview live from the 2026 International Myeloma Society (IMS) Annual Meeting, Sagar Lonial, MD, discussed the FDA approval of iberdomide, for which data were presented at the meeting, and the ...
Durability metrics included median duration of response 29.1 months and median PFS 30.2 months, with ongoing responses ...
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Puma Biotechnology has launched the phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202; NCT07465757) evaluating the investigational ...
Trispecific T-cell engagers target two tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.
The FDA has accepted a supplemental new drug application and granted priority review to elinzanetant (Lynkuet) for moderate ...
C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results